Mohs surgery is primarily used for basal cell carcinoma and squamous cell carcinoma, the two most common forms of skin cancer. It’s also used for melanoma in situ and several rarer skin cancers. The procedure is specifically designed for tumors where preserving healthy tissue matters and where the risk of the cancer coming back is high.
Basal Cell Carcinoma Is the Most Common Use
Basal cell carcinoma accounts for the largest share of Mohs procedures. This cancer grows in the outermost layer of skin and rarely spreads to distant organs, but it can be locally destructive, burrowing into surrounding tissue in unpredictable patterns. Mohs is particularly valuable for basal cell carcinomas that grow aggressively beneath the surface. These include morpheaform (scar-like) tumors, infiltrating tumors, and micronodular types, all of which tend to send invisible extensions beyond what’s visible on the skin.
The cure rates reflect why Mohs is the gold standard for these cancers. A study tracking patients over five years found recurrence rates of just 2.1% for previously untreated basal cell carcinomas and 5.2% for tumors that had already come back after an earlier treatment. That 5.2% figure is notable because recurrent basal cell carcinomas are notoriously difficult to treat. Tumors removed by standard excision that turn out to have cancer cells at the margins recur 33 to 43% of the time within two to five years. Mohs dramatically reduces that risk.
Squamous Cell Carcinoma
Squamous cell carcinoma is the second most common skin cancer treated with Mohs. Unlike basal cell carcinoma, squamous cell carcinoma carries a real (though still relatively low) risk of spreading to lymph nodes and other organs, which makes complete removal especially important. Mohs is recommended for squamous cell tumors that are large, located in high-risk areas, have aggressive growth patterns under the microscope, or have recurred after previous treatment.
Collision tumors, where basal cell and squamous cell carcinoma exist in the same lesion (sometimes called basosquamous carcinoma), are also treated with Mohs. These hybrid tumors can behave more aggressively than either cancer alone.
Melanoma in Certain Cases
Mohs surgery is used for melanoma, though in a more limited way. The strongest evidence supports its use for melanoma in situ (the earliest stage, where cancer cells haven’t grown beyond the top layer of skin), particularly a subtype called lentigo maligna. This form of melanoma commonly appears on sun-damaged facial skin in older adults, where it can spread outward in irregular, hard-to-detect margins. The American Academy of Dermatology notes that Mohs and similar staged excision techniques allow exhaustive examination of the peripheral margins while sparing tissue in areas where there isn’t much to spare, like the nose, ears, or around the eyes.
For invasive melanoma that has grown deeper into the skin, Mohs is less commonly used. Standard wide excision with predetermined margins remains the typical approach for those cases.
Rarer Skin Cancers
Beyond the big three, Mohs is used for several uncommon skin cancers. Dermatofibrosarcoma protuberans, a slow-growing tumor that develops in the deep layers of skin, is one of the best-known examples. This cancer has a strong tendency to extend far beyond its visible borders through tentacle-like projections, making it an ideal candidate for a technique built around tracking microscopic tumor extensions. Merkel cell carcinoma, sebaceous carcinoma, and other rare cutaneous tumors may also be treated with Mohs when the location or characteristics of the tumor warrant it.
Why Location Determines Whether Mohs Is Used
The type of cancer is only half the equation. Where the tumor sits on your body plays an equally important role in whether Mohs is recommended. The procedure is most commonly used for cancers on the face, especially around the nose, eyes, ears, and lips. These are areas where even a few extra millimeters of tissue removal can affect appearance or function, and where cancer recurrence rates with standard excision tend to be higher.
As a general guideline, Mohs is the preferred treatment for facial tumors larger than about 0.6 to 1 centimeter, and for tumors on the trunk or extremities larger than 2 centimeters. But size is just one factor. A small tumor on the tip of the nose with an aggressive growth pattern is a stronger candidate for Mohs than a large, well-defined tumor on the back.
Tumors that have come back after previous treatment are also strong candidates regardless of location. Recurrent cancers often grow in scar tissue, which makes their borders harder to identify visually and increases the value of the layer-by-layer examination that defines the Mohs approach.
How the Technique Differs From Standard Removal
What makes Mohs distinct from regular surgical excision is how the removed tissue gets examined. In standard excision, the surgeon cuts out the tumor with a margin of normal-looking skin and sends it to a lab, where a pathologist slices through the tissue vertically, like cutting a loaf of bread. This method only samples a small fraction of the actual margin.
In Mohs, the surgeon removes a thin layer of tissue and cuts it horizontally from the undersurface, which allows examination of the entire outer edge of the specimen, a full 360-degree view. If cancer cells are found at any point along that edge, the surgeon removes another layer from only that specific area and checks again. This cycle repeats until no cancer remains. The result is a procedure that removes 100% of the detectable cancer while taking the least possible amount of healthy skin.
What Recovery Looks Like
Most Mohs procedures are done in an outpatient office under local anesthesia. The surgery itself can take several hours because of the repeated cycles of removing and examining tissue, but you’re awake the entire time and go home the same day.
After the procedure, your surgeon will provide instructions for wound care at home and schedule follow-up appointments for stitch removal and healing checks. The wound itself heals over weeks, but full scar maturation takes longer. Expect the scar to continue flattening and fading in color for up to a year. Because skin cancers can recur or new ones can develop nearby, post-surgical checkups typically extend years into the future.